A Phase 1 interventional study of The injectable TQD3606 and meropenem in Infections, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-22.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
TQD3606 is a fixed-dose combination of meropenem and avibatam. This study is a phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQD3606 injection in a single center, randomized, double-blind, placebo-controlled, single and multiple administration in healthy subjects, and to explore the excretion of TQD3606 in urine. To evaluate the tolerability and safety of injectable TQD3606 after single and multiple dosing in healthy subjects.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's planned enrollment of 56 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
received a single dose of 0.75g TQD3606 for injection
Drug: The injectable TQD3606
First, a single dose of 0.5g of meropenem for injection was administered for 0.5h intravenous infusion; after washout for at least 2 days, 0.75g of TQD3606 for injection was administered for 1h intravenous infusion; for at least 2 days of washout, 0.75g was administered A single dose of TQD3606 for injection was administered for 2 hours, and the elution time was at least 2 days. Finally, a single dose of 0.75 g of TQD3606 for injection was administered, and the duration of intravenous infusion was 3 hours.
Drug: The injectable TQD3606 · Drug: meropenem
According to the random table, they were divided into two groups, A and B, Group A was given 1.0g meropenem for injection (Mepin) in the first cycle, and 0.5g avibactam sodium for injection in the second cycle. The third cycle was given 1.5g TQD3606 for injection; group B was given 0.5g avibactam sodium for injection in the first cycle, 1.0g meropenem (Mepin) for injection in the second cycle, and 1.5g for injection in the third cycle TQD3606.
Drug: The injectable TQD3606 · Drug: meropenem · Drug: Avibactam Sodium
First, 0.75g TQD3606 for injection was administered multiple times (Dosing every 8 hours, 3 consecutive doses), and at least 2 days were washed out after the last dose; then 1.125g TQD3606 for injection was administered multiple times (Dosing every 12 hours, 2 consecutive doses) times), wash out at least 2 days after the last administration; finally, a single administration of 2.25 g of TQD3606 for injection (Dosing every 12 hours, once administered). Intravenous infusion for 3 hours.
Drug: The injectable TQD3606
First, a single dose of 3.0g TQD3606 for injection/placebo was administered, intravenous infusion for 3hours, and washout for at least 3 days; then multiple doses of 3.0g TQD3606 for injection/placebo were administered (Dosing every 8 hours, 10 consecutive doses) , the intravenous infusion duration is 3hours.
Drug: The injectable TQD3606 · Drug: Placebo
TQD3606 is a fixed-dose combination of meropenem and avibatam.
Meropenem is a carbapenem antibiotic
Avibactam is beta-lactamase inhibitor.
It is a placebo.
Maximum Concentration (Cmax)
Maximum Concentration
Time frame: 1 hour before administration,to 24 hours after administration.
Area under the plasma concentration-time curve from initial dosing to 24 hours (AUC0-24)
Area under the plasma concentration-time curve from initial dosing to 24 hours
Time frame: 1 hour before administration,to 24 hours after administration.
Time to maximum concentration following drug administration (Tmax)
Time to maximum concentration following drug administration
Time frame: 1 hour before administration,to 24 hours after administration.
Apparent terminal elimination half-life following drug administration (t1/2)
Apparent terminal elimination half-life following drug administration
Time frame: 1 hour before administration,to 24 hours after administration.
Area under plasma concentration-time curve from first dosing to last measurable concentration point (AUC0-t)
Area under plasma concentration-time curve from first dosing to last measurable concentration point
Time frame: 1 hour before administration,to 24 hours after administration.
The amount of drug excreted through urine 24 hours after administration (Ae0-24)
The amount of drug excreted through urine 24 hours after administration
Time frame: 1 hour before administration,to 24 hours after administration.
Cumulative excretion rate of drugs through urine
Cumulative excretion rate of drugs through urine
Time frame: 1 hour before administration,to 24 hours after administration.
The total clearance (CLt) The total clearance (CLt)
The total clearance
Time frame: 1 hour before administration,to 24 hours after administration.
Renal clearance (CLr)
Renal clearance
Time frame: 1 hour before administration,to 24 hours after administration.
Elimination rate constant(λz)
Elimination rate constant
Time frame: 1 hour before administration,to 24 hours after administration.
Apparent volume of distribution (Vd/F)
Apparent volume of distribution
Time frame: 1 hour before administration,to 24 hours after administration.
Mean residence time (MRT)
Mean residence time
Time frame: 1 hour before administration,to 24 hours after administration.
Valley concentration (Cmin,ss)
Valley concentration
Time frame: Within 60 minutes before 8th to 10th administration and 24 hours after 10th administration
Accumulation index
Accumulation index
Time frame: Within 60 minutes before 8th to 10th administration and 24 hours after 10th administration
Adverse event rate
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
Time frame: Baseline up to 24 hours after administration
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Monitor the safety indicators of subjects during the trial
Time frame: Baseline up to 24 hours after administration
Body temperature
Monitor the safety indicators of subjects during the trial
Time frame: 1 hour before administration and 24 hours after administration
Pulse
Monitor the safety indicators of subjects during the trial
Time frame: 1 hour before administration and 24 hours after administration
Systolic and diastolic blood pressure
Monitor the safety indicators of subjects during the trial
Time frame: 1 hour before administration and 24 hours after administration
Number of participants with abnormal laboratory test results
Monitor the safety indicators of subjects during the trial
Time frame: Baseline up to 24 hours after administration
Start is estimated for Apr 2022; primary completion for Dec 2023, 20 months later.
Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's planned 20 months is above that.
Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →